Movement Alert|Revolution Medicines, Inc. Intraday Rise 4.21% in Regular Trading, Updated Rasonque clinical data lifted sentiment

Market Focus
Nov 20

On November 20, Revolution Medicines, Inc. posted an Intraday Rise of 4.21% in Regular Trading, trading at $167.56/share, with turnover of $163.0 million.

The move was closely tied to updated Phase 1/2 data for Rasonque plus chemotherapy in previously untreated metastatic pancreatic cancer, where the company reported a 60.7% objective response rate and durable tumor responses, with safety consistent with prior observations.

The update also reinforced the rationale for the ongoing Phase 3 RASolute 303 study. As added context, the company had just received European Commission approval for Rasonque as a monotherapy for metastatic pancreatic adenocarcinoma across EU and EEA markets, based on a Phase 3 trial that met all primary and key secondary endpoints, supporting investor expectations for broader commercialization and indication expansion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10